Related Experiment Video
Updated: Jun 14, 2025
05:46
Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography
Published on: December 2, 2022
1.7K
Melatonin Receptor Expression in Primary Uveal Melanoma.
Anna Hagström1, Ruba Kal Omar1, Hans Witzenhausen1
1Department of Clinical Neuroscience, Division of Eye and Vision, Karolinska Institutet, 171 77 Stockholm, Sweden.
International Journal of Molecular Sciences
|August 29, 2024
Summary
Melatonin receptors are present in uveal melanoma (UM). Higher melatonin receptor 1A (MTNR1A) expression was linked to mortality, but did not impact survival outcomes in UM patients.
Area of Science:
- Oncology
- Molecular Biology
- Ophthalmology
Background:
- Melatonin exhibits anti-cancer properties across several malignancies.
- Uveal melanoma (UM) is a primary intraocular malignancy.
- Melatonin's therapeutic potential in UM warrants investigation.
Purpose of the Study:
- To assess melatonin receptor expression in primary UM tissues.
- To correlate receptor expression with UM-related mortality and prognostic factors.
Main Methods:
- Immunohistochemistry was performed on 47 primary UM tissues.
- TCGA data from 80 UM patients were analyzed for RNA expression.
- Kaplan-Meier analysis was used to evaluate survival probabilities.
Main Results:
- Low expression of melatonin receptor 1A (MTNR1A) and 1B (MTNR1B) was observed.
- MTNR1A expression was significantly higher in patients who died from UM.
- Higher MTNR1A RNA levels correlated with BAP1 mutations; higher NQO2 RNA levels correlated with epithelioid cell type.
- No significant survival differences were found based on receptor expression.
Conclusions:
- Melatonin receptors are expressed in UM, suggesting a role in melatonin's anti-cancer mechanisms.
- While MTNR1A expression is associated with UM mortality, it does not predict survival outcomes.
- Further research is needed to elucidate melatonin's role in UM pathogenesis and treatment.
